Price Trends,repair damaged mitochondria

Stealth Peptides International, a name now synonymous with groundbreaking advancements in biopharmaceutical research, has evolved into Stealth BioTherapeutics Corp. This transition, occurring in June 2015, marked a significant step for the company, which had established itself as an innovative biopharmaceutical company dedicated to addressing complex diseases. At its core, Stealth Peptides International has focused on developing novel therapies for conditions rooted in mitochondrial dysfunction, the cellular powerhouses responsible for energy production within our bodies.

The company's journey began with a deep understanding of peptides, specifically aromatic-cationic peptides, and their potential to interact with and support cellular health. Early research, as evidenced by publications such as "Stealth Peptides Target Cellular Powerhouses to Fight Rare and Common Age-Related Diseases," highlighted the capacity of these peptides to repair damaged mitochondria and promote cellular repair, thereby restoring function. This foundational work led to the development of key compounds, including Bendavia, which demonstrated the ability to maintain mitochondrial bioenergetics, such as membrane potential and respiration, under stress.

A significant milestone for Stealth Peptides International was its lead compound, elamipretide (formerly known as MTP 131 or SS-31). This aromatic-cationic mitochondria-targeting tetrapeptide has been at the forefront of the company's clinical development efforts. Elamipretide has shown promise in clinical trials for various conditions. For instance, Stealth's injection, to be sold as Forzinity for Barth syndrome, an X-linked genetic disorder that weakens the heart and other muscles, received FDA approval. This marked a critical advancement, as there were previously no FDA or EMA-approved therapies for Barth syndrome. The company also pursued accelerated approval for elamipretide in the treatment of this rare mitochondrial disease.

The company's patent portfolio further underscores its commitment to innovation. Stealth BioTherapeutics Corp's patent for aromatic-cationic peptides aims to prevent drug-induced neuropathy and enhance cellular resilience. This includes methods for preventing or treating conditions like vitiligo by administering effective amounts of these specialized peptides.

Operating as Stealth Peptides International Inc initially, the company was incorporated in April 2006 as an exempted company with limited liability. Its presence has extended globally, with entities like Stealth Peptides International Shanghai Inc contributing to its research and development endeavors. The company's evolution from Stealth Peptides International, Inc. to Stealth BioTherapeutics Corp signifies its growth and expanding focus within the biopharmaceutical landscape.

Today, Stealth BioTherapeutics stands as an innovative, clinical stage biopharmaceutical company committed to bringing mitochondria-targeted therapies to patients. Its areas of interest encompass rare genetic disorders involving mitochondrial dysfunction, neurodegenerative disorders, and ophthalmic disorders. The company's mission remains to develop novel therapies that improve the lives of individuals affected by diseases of the mitochondria. As a privately held clinical-stage biotechnology company, Stealth BioTherapeutics continues to leverage its expertise in peptides and mitochondrial biology to address unmet medical needs and pioneer new frontiers in medicine.